SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Herc who wrote (3522)7/30/1999 10:03:00 PM
From: BMcV  Read Replies (1) of 10280
 
One problem is that your comparables are in a different business. SEPR is not a process/platform company, though it was, historically, and still has some ambitions in that area. That is not a great business, given the intense competition and the limited markets for high throughput screening machines and so forth. In contrast, SEPR's potential markets are huge and ubiquitous: allergies, asthma, heart-burn, depression. They have several candidates in each of those areas, any one of which could turn into a blockbuster. Take a look at Immunex, or the $4 billion J&J just shelled out for Centocor, to get an idea what one big drug is worth.

>>Are you all in love with the stock?<<

At this point, I'd say it's more a love/hate thing.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext